Immune status consisting of non-production of HIV antibodies, as determined by various serological tests.
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)
An acute infectious disease caused by the RUBELLA VIRUS. The virus enters the respiratory tract via airborne droplet and spreads to the LYMPHATIC SYSTEM.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
Immunoglobulins produced in response to VIRAL ANTIGENS.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).
Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV SEROPOSITIVITY).
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Immunologic tests for identification of HIV (HTLV-III/LAV) antibodies. They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the viral antibody from patients with overt symptoms of AIDS or AIDS-RELATED COMPLEX.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
Sexual activities of humans.
Sexual attraction or relationship between males.
Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviors whose outcomes may present a risk to the individual or to those associated with him or her.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
Agents used to treat RETROVIRIDAE INFECTIONS.
A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.
A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process.
A republic in southern Africa, the southernmost part of Africa. It has three capitals: Pretoria (administrative), Cape Town (legislative), and Bloemfontein (judicial). Officially the Republic of South Africa since 1960, it was called the Union of South Africa 1910-1960.
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
Cellular receptors that bind the human immunodeficiency virus that causes AIDS. Included are CD4 ANTIGENS, found on T4 lymphocytes, and monocytes/macrophages, which bind to the HIV ENVELOPE PROTEIN GP120.
Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene.
Married or single individuals who share sexual relations.
Abuse, overuse, or misuse of a substance by its injection into a vein.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
Persons who have experienced prolonged survival of HIV infection. This includes the full spectrum of untreated, HIV-infected long-term asymptomatics to those with AIDS who have survived due to successful treatment.
A sheath that is worn over the penis during sexual behavior in order to prevent pregnancy or spread of sexually transmitted disease.
Sexual behaviors which are high-risk for contracting SEXUALLY TRANSMITTED DISEASES or for producing PREGNANCY.
Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
A republic in eastern Africa, south of SUDAN and west of KENYA. Its capital is Kampala.
A republic in southern Africa, east of ZAMBIA and BOTSWANA and west of MOZAMBIQUE. Its capital is Harare. It was formerly called Rhodesia and Southern Rhodesia.

Tuberculous meningitis in South African urban adults. (1/803)

We retrospectively reviewed 56 adults with culture-proven tuberculous meningitis (TBM), investigating clinical signs, cerebrospinal fluid (CSF) findings and outcome. There were 50 patients, aged 18-59 years, 39 with and 11 without human immunodeficiency virus (HIV) infection. Six were aged 60 years or older. Neurological signs of TBM in 18-59-year-olds were unaffected by HIV serostatus while, compared to those > or = 60 years of age, there were more patients with meningism (86.0% vs. 33.3%; p = 0.011) and fewer with seizures (12.0% vs. 50.0%; p = 0.046). The HIV-infected 18-59-year-olds had significantly more extrameningeal tuberculosis compared to the non-HIV-infected (76.9% vs. 9.1%; p = 0.0001) and 23.1% had 'breakthrough' TBM. CSF analysis revealed 12 patients (21.4%) with acellular fluid (more common in those > or = 60 years of age, p = 0.016), of whom three had completely normal CSF. A neutrophil predominance was found in 22 patients (39.3%). Only three patients (5.4%) had a positive CSF smear for acid-fast bacilli. In-hospital mortality occurred in 39 patients (69.1%), was similar in all study groups, and was not related to neurological stage. The diagnosis of TBM can be masked by lack of meningism in the elderly and by atypical CSF findings.  (+info)

Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. (2/803)

BACKGROUND: Human papillomavirus (HPV) infection is associated with precancerous cervical squamous intraepithelial lesions commonly seen among women infected with human immunodeficiency virus-1 (HIV). We characterized HPV infection in a large cohort of HIV-positive and HIV-negative women participating in the Women's Interagency HIV Study to determine the prevalence of and risk factors for cervicovaginal HPV infection in HIV-positive women. METHODS: HIV-positive (n = 1778) and HIV-negative (n = 500) women were tested at enrollment for the presence of HPV DNA in a cervicovaginal lavage specimen. Blood samples were tested for HIV antibody status, level of CD4-positive T cells, and HIV RNA load (copies/mL). An interview detailing risk factors was conducted. Univariate and multivariate analyses were performed. RESULTS: Compared with HIV-negative women, HIV-positive women with a CD4+ cell count of less than 200/mm3 were at the highest risk of HPV infection, regardless of HIV RNA load (odds ratio [OR] = 10.13; 95% confidence interval [CI] = 7.32-14.04), followed by women with a CD4+ count greater than 200/mm3 and an HIV RNA load greater than 20,000 copies/mL (OR = 5.78; 95% CI = 4.17-8.08) and women with a CD4+ count greater than 200/mm3 and an HIV RNA load less than 20,000 copies/mL (OR = 3.12; 95% CI = 2.36-4.12), after adjustment for other factors. Other risk factors among HIV-positive women included racial/ethnic background (African-American versus Caucasian, OR = 1.64; 95% CI = 1.19-2.28), current smoking (yes versus no; OR = 1.55; 95% CI = 1.20-1.99), and younger age (age < 30 years versus > or = 40 years; OR = 1.75; 95% CI = 1.23-2.49). CONCLUSIONS: Although the strongest risk factors of HPV infection among HIV-positive women were indicators of more advanced HIV-related disease, other factors commonly found in studies of HIV-negative women, including racial/ethnic background, current smoking, and age, were important in HIV-positive women as well.  (+info)

Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. (3/803)

In order to investigate the seroprevalence of human herpesvirus 8 (HHV-8) infection in central and southern Italy, sera from human immunodeficiency virus (HIV)-seronegative subjects, with and without Kaposi's sarcoma (KS), were analyzed by immunofluorescence assay, using BC-3, a cell line latently infected with HHV-8. High titers of antibody against HHV-8 lytic and latent antigens were detected in all 50 KS patients studied, while in 50 HIV-seronegative subjects without KS, 32 (64%) were found positive for HHV-8 antibodies. Titers in the sera of these patients were lower than those for KS patients. This data suggests that HHV-8 infection is not restricted to KS patients and that the prevalence of HHV-8 infection in the general population may be correlated with differing rates of prevalence of KS in different parts of the world. In view of these findings, possible nonsexual transmission routes were evaluated. Nested PCR was used to test for the presence of HHV-8 DNA in saliva, urine, and tonsillar swabs from KS and non-KS patients. In KS patients, 14 out of 32 tonsillar swabs (43.7%), 11 out of 24 saliva samples (45.8%), and just 2 out of 24 urine samples (8.3%) tested positive for HHV-8 DNA. In the control group, on the contrary, none of the 20 saliva and 20 urine specimens was positive for HHV-8 DNA; only 1 out of 22 tonsillar swabs gave a positive result. This data supports the hypothesis that HHV-8 infects the general population in a latent form. The reactivation of viral infection may result in salivary shedding of HHV-8, contributing to viral spread by nonsexual transmission routes.  (+info)

Cardiac autoimmunity in HIV related heart muscle disease. (4/803)

OBJECTIVE: To assess the frequency of circulating cardiac specific autoantibodies in HIV positive patients with and without echocardiographic evidence of left ventricular dysfunction. SUBJECTS: 74 HIV positive patients including 28 with echocardiographic evidence of heart muscle disease, 52 HIV negative people at low risk of HIV infection, and 14 HIV negative drug users who had all undergone non-invasive cardiac assessment were studied along with a group of 200 healthy blood donors. RESULTS: Cardiac autoantibodies detected by indirect immunofluorescence (serum dilution 1/10) were more common in the HIV positive patients (15%), particularly the HIV heart muscle disease group (21%), than in HIV negative controls (3.5%) (both p < 0.001). By ELISA (dilution 1/320), abnormal anti-alpha myosin autoantibody concentrations were found more often in HIV patients with heart muscle disease (43%) than in HIV positive patients with normal hearts (19%) or in HIV negative controls (3%) (p < 0.05 and p < 0.001, respectively). Anti-alpha myosin autoantibody concentrations were greater in HIV positive patients than in HIV negative controls, regardless of cardiac status ((mean SD) 0.253 (0.155) v 0.170 (0.076); p = 0.003). In particular the mean antibody concentration was higher in the HIV heart muscle disease patients (0.291 (0.160) v 0.170 (0.076); p = 0.001) than in HIV negative controls. On follow up, six subjects with normal echocardiograms but raised autoantibody concentrations had died after a median of 298 days, three with left ventricular abnormalities at necropsy. This compared with a median survival of 536 days for 21 HIV positive patients with normal cardiological and immunological results. CONCLUSIONS: There is an increased frequency of circulating cardiac specific autoantibodies in HIV positive individuals, particularly those with heart muscle disease. The data support a role for cardiac autoimmunity in the pathogenesis of HIV related heart muscle disease, and suggest that cardiac autoantibodies may be markers of the development of left ventricular dysfunction in HIV positive patients with normal hearts.  (+info)

Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. (5/803)

A new test that measures interferon-gamma (IFN-gamma) release in whole blood following stimulation with tuberculin has the potential to detect tuberculosis infection using a single blood draw. The IFN-gamma release assay was compared with the standard tuberculin skin test (TST) among 467 intravenous drug users at risk for tuberculosis in urban Baltimore. Among 300 human immunodeficiency virus (HIV)-seronegative patients, the IFN-gamma release assay was positive in 177 (59%), whereas the TST was positive in 71 (24%), for a percent agreement of 59% (kappa=26%). Among 167 HIV-seropositive subjects, the IFN-gamma release assay identified 32 reactors (19%); the TST identified 16 reactors (9.6%), for a percent agreement of 82% (kappa=28%). The IFN-gamma release assay detected more reactors than did the TST, but its agreement with TST was weak. As the TST is an imperfect standard, further evaluation of the IFN-gamma release assay among uninfected persons and persons with culture-confirmed tuberculosis will be useful.  (+info)

Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. (6/803)

To assess possible differences in immune status, proportions and absolute numbers of subsets of CD4+ and CD8+ T cells were compared between HIV- healthy Ethiopians (n = 52) and HIV- Dutch (n = 60). Both proportions and absolute numbers of naive CD4+ and CD8+ T cells were found to be significantly reduced in HIV Ethiopians compared with HIV- Dutch subjects. Also, both proportions and absolute numbers of the effector CD8+ T cell population as well as the CD4+CD45RA-CD27- and CD8+CD45RA-CD27- T cell populations were increased in Ethiopians. Finally, both proportions and absolute numbers of CD4+ and CD8+ T cells expressing CD28 were significantly reduced in Ethiopians versus Dutch. In addition, the possible association between the described subsets and HIV status was studied by comparing the above 52 HIV- individuals with 32 HIV+ Ethiopians with CD4 counts > 200/microliter and/or no AIDS-defining conditions and 39 HIV+ Ethiopians with CD4 counts < 200/microliter or with AIDS-defining conditions. There was a gradual increase of activated CD4+ and CD8+ T cells, a decrease of CD8+ T cells expressing CD28 and a decrease of effector CD8+ T cells when moving from HIV- to AIDS. Furthermore, a decrease of naive CD8+ T cells and an increase of memory CD8+ T cells in AIDS patients were observed. These results suggest a generally and persistently activated immune system in HIV- Ethiopians. The potential consequences of this are discussed, in relation to HIV infection.  (+info)

CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. (7/803)

The predominant immunological finding in HIV+ haemophilia patients is a decrease of CD4+ lymphocytes during progression of the disease. Depletion of CD4+ lymphocytes is paralleled by an increase in the proportion of immune complex-coated CD4+ cells. We examined the hypothesis that the formation of immune complexes on CD4+ lymphocytes is followed by rapid clearance of immune complex-coated CD4+ lymphocytes from the circulation. In this study, the relationship of relative to absolute numbers of immune complex-loaded CD4+ blood lymphocytes and their association with viral load were studied. Two measurements of relative and absolute numbers of gp120-, IgG- and/or IgM-loaded CD4+ lymphocytes were analysed in HIV+ and HIV- haemophilia patients, with a median interval of approx. 3 years. Immune complexes on CD4+ lymphocytes were determined using double-fluorescence flow cytometry and whole blood samples. Viral load was assessed using NASBA and Nuclisens kits. Whereas the proportion of immune complex-coated CD4+ lymphocytes increased with progression of the disease, absolute numbers of immune complex-coated CD4+ lymphocytes in the blood were consistently low. Relative increases of immune complex-coated CD4+ blood lymphocytes were significantly associated with decreases of absolute numbers of circulating CD4+ lymphocytes. The gp120 load on CD4+ blood lymphocytes increased in parallel with the viral load in the blood. These results indicate that immune complex-coated CD4+ lymphocytes are rapidly cleared from the circulation, suggesting that CD4+ reactive autoantibodies and immune complexes are relevant factors in the pathogenesis of AIDS. Relative increases of immune complex-positive cells seem to be a consequence of both an increasing retroviral activity as well as a stronger loading with immune complexes of the reduced number of CD4+ cells remaining during the process of CD4 depletion. The two mechanisms seem to enhance each other and contribute to the progressive CD4 decrease during the course of the disease.  (+info)

Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. (8/803)

To examine the protective role of cellular immunity in the vertical transmission of HIV, we analyzed HIV-specific IL-2 and CTL responses, as well as beta-chemokine expression in HIV-infected and uninfected infants of HIV+ mothers. Our results showed that HIV envelope (env) peptide-specific IL-2 responses associated with beta-chemokine production were detectable at birth in the majority of uninfected infants of HIV+ mothers. The responses falling to background before the infants were 1 yr old were rarely associated with HIV-specific CTL activity. Conversely, HIV-specific Th and CTL cellular responses were absent at birth in HIV-infected infants. Infants with AIDS-related symptoms exhibited undetectable or very low levels of HIV-specific cellular immunity during the first year of life, whereas those with a slowly progressive disease showed evidence of such immunity between their second and ninth month. The latter group of infected infants tested negative for plasma HIV RNA levels shortly after birth, suggesting lack of intrauterine exposure to HIV. The presence of HIV-specific Th responses at birth in uninfected newborns of HIV+ mothers, but absence of such activities in HIV-infected infants without evidence of intrauterine HIV infection, suggests that in utero development of HIV-specific Th responses associated with beta-chemokines could mediate nonlytic inhibition of infection during vertical transmission of HIV.  (+info)

HIV seronegativity is a term used to describe a person who has tested negative for HIV (Human Immunodeficiency Virus) antibodies in their blood. This means that the individual does not show evidence of current or past infection with HIV, which can cause AIDS (Acquired Immune Deficiency Syndrome). However, it's important to note that there is a window period after initial infection during which a person may test negative for HIV antibodies, even though they are indeed infected. This window period typically lasts between 2-6 weeks but can extend up to 3 months in some cases. Therefore, if someone believes they have been exposed to HIV, they should consider getting tested again after this window period has passed.

Mumps is a viral infection that primarily affects the parotid salivary glands, causing them to swell and become painful. The medical definition of mumps is: "An acute infectious disease, caused by the mumps virus, characterized by painful enlargement of one or more of the salivary glands, especially the parotids."

The infection spreads easily through respiratory droplets or direct contact with an infected person's saliva. Symptoms typically appear 16-18 days after exposure and include fever, headache, muscle aches, tiredness, and swollen, tender salivary glands. Complications of mumps are rare but can be serious and include meningitis, encephalitis, deafness, and inflammation of the reproductive organs in males.

Prevention is through vaccination with the measles-mumps-rubella (MMR) vaccine, which is part of routine childhood immunization schedules in many countries.

Rubella, also known as German measles, is a viral infection that primarily affects the skin and lymphatic system. It is caused by the rubella virus. The disease is typically mild with symptoms such as low-grade fever, sore throat, swollen glands (especially around the ears and back of the neck), and a rash that starts on the face and spreads to the rest of the body.

Rubella is preventable through vaccination, and it's part of the MMR (measles, mumps, and rubella) vaccine. It's crucial to get vaccinated against rubella because if a pregnant woman gets infected with the virus, it can cause serious birth defects in her unborn baby, including hearing impairment, eye abnormalities, heart problems, and developmental delays. This condition is called congenital rubella syndrome (CRS).

It's worth noting that rubella has been largely eliminated from many parts of the world due to widespread vaccination programs, but it still remains a public health concern in areas with low vaccination rates or where access to healthcare is limited.

Seroepidemiologic studies are a type of epidemiological study that measures the presence and levels of antibodies in a population's blood serum to investigate the prevalence, distribution, and transmission of infectious diseases. These studies help to identify patterns of infection and immunity within a population, which can inform public health policies and interventions.

Seroepidemiologic studies typically involve collecting blood samples from a representative sample of individuals in a population and testing them for the presence of antibodies against specific pathogens. The results are then analyzed to estimate the prevalence of infection and immunity within the population, as well as any factors associated with increased or decreased risk of infection.

These studies can provide valuable insights into the spread of infectious diseases, including emerging and re-emerging infections, and help to monitor the effectiveness of vaccination programs. Additionally, seroepidemiologic studies can also be used to investigate the transmission dynamics of infectious agents, such as identifying sources of infection or tracking the spread of antibiotic resistance.

Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.

Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.

There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.

In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

HIV (Human Immunodeficiency Virus) infection is a viral illness that progressively attacks and weakens the immune system, making individuals more susceptible to other infections and diseases. The virus primarily infects CD4+ T cells, a type of white blood cell essential for fighting off infections. Over time, as the number of these immune cells declines, the body becomes increasingly vulnerable to opportunistic infections and cancers.

HIV infection has three stages:

1. Acute HIV infection: This is the initial stage that occurs within 2-4 weeks after exposure to the virus. During this period, individuals may experience flu-like symptoms such as fever, fatigue, rash, swollen glands, and muscle aches. The virus replicates rapidly, and the viral load in the body is very high.
2. Chronic HIV infection (Clinical latency): This stage follows the acute infection and can last several years if left untreated. Although individuals may not show any symptoms during this phase, the virus continues to replicate at low levels, and the immune system gradually weakens. The viral load remains relatively stable, but the number of CD4+ T cells declines over time.
3. AIDS (Acquired Immunodeficiency Syndrome): This is the most advanced stage of HIV infection, characterized by a severely damaged immune system and numerous opportunistic infections or cancers. At this stage, the CD4+ T cell count drops below 200 cells/mm3 of blood.

It's important to note that with proper antiretroviral therapy (ART), individuals with HIV infection can effectively manage the virus, maintain a healthy immune system, and significantly reduce the risk of transmission to others. Early diagnosis and treatment are crucial for improving long-term health outcomes and reducing the spread of HIV.

HIV seropositivity is a term used to describe a positive result on an HIV antibody test. This means that the individual has developed antibodies against the Human Immunodeficiency Virus (HIV), indicating that they have been infected with the virus. However, it's important to note that this does not necessarily mean that the person has AIDS, as there can be a long period between HIV infection and the development of AIDS.

HIV seroprevalence refers to the proportion or percentage of a population that has antibodies against the Human Immunodeficiency Virus (HIV) in their blood, indicating current or previous HIV infection. It is often determined through serological testing methods that detect the presence of HIV antibodies in blood samples. The data from HIV seroprevalence studies are essential for understanding the spread and distribution of HIV within a specific population or geographic area, helping to inform public health policies and interventions aimed at controlling and preventing HIV transmission.

HIV-1 (Human Immunodeficiency Virus type 1) is a species of the retrovirus genus that causes acquired immunodeficiency syndrome (AIDS). It is primarily transmitted through sexual contact, exposure to infected blood or blood products, and from mother to child during pregnancy, childbirth, or breastfeeding. HIV-1 infects vital cells in the human immune system, such as CD4+ T cells, macrophages, and dendritic cells, leading to a decline in their numbers and weakening of the immune response over time. This results in the individual becoming susceptible to various opportunistic infections and cancers that ultimately cause death if left untreated. HIV-1 is the most prevalent form of HIV worldwide and has been identified as the causative agent of the global AIDS pandemic.

AIDS serodiagnosis refers to the detection and confirmation of HIV (Human Immunodeficiency Virus) infection through the identification of antibodies produced by the immune system in response to the virus. These antibodies are typically detected in blood samples using various testing methods, such as ELISA (Enzyme-Linked Immunosorbent Assay) and Western blot. A positive result in both tests indicates a high probability of HIV infection and progression to AIDS (Acquired Immune Deficiency Syndrome), provided the individual has not been recently infected, as it may take several weeks for the antibodies to develop and become detectable. Regular testing and early diagnosis are crucial for timely medical intervention, treatment, and prevention of further transmission.

HIV antigens refer to the proteins present on the surface or within the human immunodeficiency virus (HIV), which can stimulate an immune response in the infected individual. These antigens are recognized by the host's immune system, specifically by CD4+ T cells and antibodies, leading to their activation and production. Two significant HIV antigens are the HIV-1 p24 antigen and the gp120/gp41 envelope proteins. The p24 antigen is a capsid protein found within the viral particle, while the gp120/gp41 complex forms the viral envelope and facilitates viral entry into host cells. Detection of HIV antigens in clinical settings, such as in the ELISA or Western blot tests, helps diagnose HIV infection and monitor disease progression.

Anti-HIV agents are a class of medications specifically designed to treat HIV (Human Immunodeficiency Virus) infection. These drugs work by interfering with various stages of the HIV replication cycle, preventing the virus from infecting and killing CD4+ T cells, which are crucial for maintaining a healthy immune system.

There are several classes of anti-HIV agents, including:

1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): These drugs act as faulty building blocks that the virus incorporates into its genetic material, causing the replication process to halt. Examples include zidovudine (AZT), lamivudine (3TC), and tenofovir.
2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): These medications bind directly to the reverse transcriptase enzyme, altering its shape and preventing it from functioning properly. Examples include efavirenz, nevirapine, and rilpivirine.
3. Protease Inhibitors (PIs): These drugs target the protease enzyme, which is responsible for cleaving viral polyproteins into functional components. By inhibiting this enzyme, PIs prevent the formation of mature, infectious virus particles. Examples include atazanavir, darunavir, and lopinavir.
4. Integrase Strand Transfer Inhibitors (INSTIs): These medications block the integrase enzyme, which is responsible for inserting the viral genetic material into the host cell's DNA. By inhibiting this step, INSTIs prevent the virus from establishing a permanent infection within the host cell. Examples include raltegravir, dolutegravir, and bictegravir.
5. Fusion/Entry Inhibitors: These drugs target different steps of the viral entry process, preventing HIV from infecting CD4+ T cells. Examples include enfuvirtide (T-20), maraviroc, and ibalizumab.
6. Post-Attachment Inhibitors: This class of medications prevents the virus from attaching to the host cell's receptors, thereby inhibiting infection. Currently, there is only one approved post-attachment inhibitor, fostemsavir.

Combination therapy using multiple classes of antiretroviral drugs has been shown to effectively suppress viral replication and improve clinical outcomes in people living with HIV. Regular adherence to the prescribed treatment regimen is crucial for maintaining an undetectable viral load and reducing the risk of transmission.

Acquired Immunodeficiency Syndrome (AIDS) is a chronic, life-threatening condition caused by the Human Immunodeficiency Virus (HIV). AIDS is the most advanced stage of HIV infection, characterized by the significant weakening of the immune system, making the person more susceptible to various opportunistic infections and cancers.

The medical definition of AIDS includes specific criteria based on CD4+ T-cell count or the presence of certain opportunistic infections and diseases. According to the Centers for Disease Control and Prevention (CDC), a person with HIV is diagnosed with AIDS when:

1. The CD4+ T-cell count falls below 200 cells per cubic millimeter of blood (mm3) - a normal range is typically between 500 and 1,600 cells/mm3.
2. They develop one or more opportunistic infections or cancers that are indicative of advanced HIV disease, regardless of their CD4+ T-cell count.

Some examples of these opportunistic infections and cancers include:

* Pneumocystis pneumonia (PCP)
* Candidiasis (thrush) affecting the esophagus, trachea, or lungs
* Cryptococcal meningitis
* Toxoplasmosis of the brain
* Cytomegalovirus disease
* Kaposi's sarcoma
* Non-Hodgkin's lymphoma
* Invasive cervical cancer

It is important to note that with appropriate antiretroviral therapy (ART), people living with HIV can maintain their CD4+ T-cell counts, suppress viral replication, and prevent the progression to AIDS. Early diagnosis and consistent treatment are crucial for managing HIV and improving life expectancy and quality of life.

HIV Protease Inhibitors are a class of antiretroviral medications used in the treatment of HIV infection. They work by blocking the activity of the HIV protease enzyme, which is necessary for the virus to replicate and infect new cells. By inhibiting this enzyme, the medication prevents the virus from maturing and assembling into new infectious particles.

HIV protease inhibitors are often used in combination with other antiretroviral drugs as part of a highly active antiretroviral therapy (HAART) regimen. This approach has been shown to effectively suppress viral replication, reduce the amount of virus in the bloodstream (viral load), and improve the health and longevity of people living with HIV.

Examples of HIV protease inhibitors include saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, atazanavir, darunavir, and tipranavir. These medications are usually taken orally in the form of tablets or capsules, and may be prescribed alone or in combination with other antiretroviral drugs.

It is important to note that HIV protease inhibitors can have significant side effects, including gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain, as well as metabolic changes such as increased cholesterol and triglyceride levels. Therefore, regular monitoring of liver function, lipid levels, and other health parameters is necessary to ensure safe and effective use of these medications.

Sexual behavior refers to any physical or emotional interaction that has the potential to lead to sexual arousal and/or satisfaction. This can include a wide range of activities, such as kissing, touching, fondling, oral sex, vaginal sex, anal sex, and masturbation. It can also involve the use of sexual aids, such as vibrators or pornography.

Sexual behavior is influenced by a variety of factors, including biological, psychological, social, and cultural influences. It is an important aspect of human development and relationships, and it is essential to healthy sexual functioning and satisfaction. However, sexual behavior can also be associated with risks, such as sexually transmitted infections (STIs) and unintended pregnancies, and it is important for individuals to engage in safe and responsible sexual practices.

It's important to note that sexual behavior can vary widely among individuals and cultures, and what may be considered normal or acceptable in one culture or context may not be in another. It's also important to recognize that all individuals have the right to make informed decisions about their own sexual behavior and to have their sexual rights and autonomy respected.

Medical definitions are often provided by authoritative medical bodies such as the World Health Organization (WHO) or the American Psychiatric Association (APA). It's important to note that these organizations have evolved their understanding and classification of homosexuality over time.

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), produced by the APA, sexual orientation is not considered a mental disorder. The manual does not provide a definition or classification for 'homosexuality, male' as a medical condition.

The current understanding in the medical community is that homosexuality is a normal and natural variation of human sexual orientation. It is not considered a disorder or an illness. The World Health Organization (WHO) removed homosexuality from its list of mental disorders in 1990.

In the context of medicine, risk-taking refers to the decision-making process where an individual or a healthcare provider knowingly engages in an activity or continues a course of treatment despite the potential for negative outcomes or complications. This could include situations where the benefits of the action outweigh the potential risks, or where the risks are accepted as part of the process of providing care.

For example, a patient with a life-threatening illness may choose to undergo a risky surgical procedure because the potential benefits (such as improved quality of life or increased longevity) outweigh the risks (such as complications from the surgery or anesthesia). Similarly, a healthcare provider may prescribe a medication with known side effects because the benefits of the medication for treating the patient's condition are deemed to be greater than the potential risks.

Risk-taking can also refer to behaviors that increase the likelihood of negative health outcomes, such as engaging in high-risk activities like substance abuse or dangerous sexual behavior. In these cases, healthcare providers may work with patients to identify and address the underlying factors contributing to their risky behaviors, such as mental health issues or lack of knowledge about safe practices.

A CD4 lymphocyte count is a laboratory test that measures the number of CD4 T-cells (also known as CD4+ T-cells or helper T-cells) in a sample of blood. CD4 cells are a type of white blood cell that plays a crucial role in the body's immune response, particularly in fighting off infections caused by viruses and other pathogens.

CD4 cells express a protein on their surface called the CD4 receptor, which is used by human immunodeficiency virus (HIV) to infect and destroy these cells. As a result, people with HIV infection or AIDS often have low CD4 lymphocyte counts, which can make them more susceptible to opportunistic infections and other complications.

A normal CD4 lymphocyte count ranges from 500 to 1,200 cells per cubic millimeter of blood (cells/mm3) in healthy adults. A lower than normal CD4 count is often used as a marker for the progression of HIV infection and the development of AIDS. CD4 counts are typically monitored over time to assess the effectiveness of antiretroviral therapy (ART) and to guide clinical decision-making regarding the need for additional interventions, such as prophylaxis against opportunistic infections.

Anti-retroviral agents are a class of drugs used to treat and prevent infections caused by retroviruses, most commonly the human immunodeficiency virus (HIV). These medications work by interfering with the replication process of the retrovirus, thereby preventing it from infecting and destroying immune cells.

There are several different classes of anti-retroviral agents, including:

1. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) - These drugs block the action of the reverse transcriptase enzyme, which is necessary for the retrovirus to convert its RNA into DNA.
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) - These drugs bind directly to the reverse transcriptase enzyme and alter its shape, preventing it from functioning properly.
3. Protease inhibitors (PIs) - These drugs block the action of the protease enzyme, which is necessary for the retrovirus to assemble new viral particles.
4. Integrase inhibitors (INIs) - These drugs block the action of the integrase enzyme, which is necessary for the retrovirus to integrate its DNA into the host cell's genome.
5. Fusion inhibitors - These drugs prevent the retrovirus from entering host cells by blocking the fusion of the viral and host cell membranes.
6. Entry inhibitors - These drugs prevent the retrovirus from attaching to and entering host cells.

Anti-retroviral therapy (ART) typically involves a combination of at least three different anti-retroviral agents from two or more classes, in order to effectively suppress viral replication and prevent drug resistance. Regular monitoring of viral load and CD4+ T cell counts is necessary to ensure the effectiveness of ART and make any necessary adjustments to the treatment regimen.

HIV Core Protein p24 is a structural protein that forms the cone-shaped core of the human immunodeficiency virus (HIV). It is one of the earliest and most abundant viral proteins produced during the replication cycle of HIV. The p24 antigen is often used as a marker for HIV infection in diagnostic tests, as its levels in the blood tend to correlate with the amount of virus present.

The core protein p24 plays a critical role in the assembly and infectivity of the virus. It helps to package the viral RNA and enzymes into the virion, and is also involved in the fusion of the viral and host cell membranes during infection. The p24 protein is produced by cleavage of a larger precursor protein called Gag, which is encoded by the HIV genome.

In addition to its role in the viral life cycle, p24 has also been the target of HIV vaccine development efforts, as antibodies against this protein can neutralize the virus and prevent infection. However, developing an effective HIV vaccine has proven to be a significant challenge due to the virus's ability to mutate and evade the immune system.

HIV Reverse Transcriptase is an enzyme that is encoded by the HIV-1 and HIV-2 viruses. It plays a crucial role in the replication cycle of the human immunodeficiency virus (HIV), which causes AIDS.

Reverse transcriptase is responsible for transcribing the viral RNA genome into DNA, a process known as reverse transcription. This allows the viral genetic material to integrate into the host cell's DNA and replicate along with it, leading to the production of new virus particles.

The enzyme has three distinct activities: a polymerase activity that synthesizes DNA using RNA as a template, an RNase H activity that degrades the RNA template during reverse transcription, and a DNA-dependent DNA polymerase activity that synthesizes DNA using a DNA template.

Reverse transcriptase inhibitors are a class of antiretroviral drugs used to treat HIV infection. They work by binding to and inhibiting the activity of the reverse transcriptase enzyme, thereby preventing the virus from replicating.

I'm sorry for any confusion, but "South Africa" is not a medical term or concept. It is a country located at the southernmost tip of the African continent. If you have any questions related to medical topics, I would be happy to help answer them!

HIV Envelope Protein gp120 is a glycoprotein that is a major component of the outer envelope of the Human Immunodeficiency Virus (HIV). It plays a crucial role in the viral infection process. The "gp" stands for glycoprotein.

The gp120 protein is responsible for binding to CD4 receptors on the surface of human immune cells, particularly T-helper cells or CD4+ cells. This binding initiates the fusion process that allows the virus to enter and infect the cell.

After attachment, a series of conformational changes occur in the gp120 and another envelope protein, gp41, leading to the formation of a bridge between the viral and cell membranes, which ultimately results in the virus entering the host cell.

The gp120 protein is also one of the primary targets for HIV vaccine design due to its critical role in the infection process and its surface location, making it accessible to the immune system. However, its high variability and ability to evade the immune response have posed significant challenges in developing an effective HIV vaccine.

Viral load refers to the amount or quantity of virus (like HIV, Hepatitis C, SARS-CoV-2) present in an individual's blood or bodily fluids. It is often expressed as the number of virus copies per milliliter of blood or fluid. Monitoring viral load is important in managing and treating certain viral infections, as a higher viral load may indicate increased infectivity, disease progression, or response to treatment.

HIV receptors are specific molecules found on the surface of certain human cells that the Human Immunodeficiency Virus (HIV) uses to enter and infect those cells. The two primary HIV receptors are CD4 and CCR5 or CXCR4 co-receptors.

1. CD4 Receptor: This is a glycoprotein found on the surface of helper T cells, macrophages, and dendritic cells. HIV first binds to the CD4 receptor via its envelope protein gp120. However, this binding alone is not sufficient for virus entry. The interaction between gp120 and CD4 triggers conformational changes in the viral envelope that expose the binding site for a co-receptor.

2. CCR5 or CXCR4 Co-receptors: These are chemokine receptors also found on the surface of certain cells, including helper T cells and macrophages. After HIV binds to the CD4 receptor, it interacts with either the CCR5 or CXCR4 co-receptor, which facilitates the fusion of the viral and cell membranes and the release of the viral genetic material into the host cell.

The specificity of HIV for these receptors plays a crucial role in its pathogenesis, as it determines which cells are susceptible to infection. Additionally, variations in the genes encoding these receptors can influence an individual's susceptibility to HIV infection and the rate of disease progression.

HIV Protease is a crucial enzyme that plays a significant role in the replication cycle of the Human Immunodeficiency Virus (HIV). It is responsible for cleaving or cutting specific long protein chains, produced during the translation of viral RNA, into smaller functional proteins. These proteins are essential for the formation of new virus particles.

The HIV Protease enzyme functions like a pair of molecular scissors, recognizing and cutting particular amino acid sequences in these polyprotein chains. By inhibiting this enzyme's activity with antiretroviral drugs known as protease inhibitors, the production of mature, infectious viral particles can be effectively prevented, which is a crucial component of highly active antiretroviral therapy (HAART) for managing HIV infection and reducing the risk of transmitting the virus to others.

In medical terminology, "sexual partners" refers to individuals who engage in sexual activity with each other. This can include various forms of sexual contact, such as vaginal, anal, or oral sex. The term is often used in the context of discussing sexual health and the transmission of sexually transmitted infections (STIs). It's important to note that full disclosure of sexual partners to healthcare providers can help in diagnosing and treating STIs, as well as in understanding an individual's sexual health history.

Substance abuse, intravenous, refers to the harmful or hazardous use of psychoactive substances that are introduced directly into the bloodstream through injection, for non-medical purposes. This behavior can lead to a range of short- and long-term health consequences, including addiction, dependence, and an increased risk of infectious diseases such as HIV and hepatitis C. Intravenous substance abuse often involves drugs such as heroin, cocaine, and amphetamines, and is characterized by the repeated injection of these substances using needles and syringes. The practice can also have serious social consequences, including disrupted family relationships, lost productivity, and criminal behavior.

Prevalence, in medical terms, refers to the total number of people in a given population who have a particular disease or condition at a specific point in time, or over a specified period. It is typically expressed as a percentage or a ratio of the number of cases to the size of the population. Prevalence differs from incidence, which measures the number of new cases that develop during a certain period.

HIV Long-Term Survivors are individuals who have been living with HIV for an extended period, typically defined as 10 years or more after the initial diagnosis. Despite the challenges and health complications associated with HIV infection and treatment, these survivors have successfully navigated the complexities of managing their condition and maintaining their health over the long term.

It is important to note that HIV Long-Term Survivors face unique medical and psychosocial challenges, including an increased risk of age-related comorbidities, cognitive decline, and mental health issues such as depression and anxiety. As a result, ongoing medical care and support are essential for maintaining their overall health and wellbeing.

While the definition of HIV Long-Term Survivors may vary depending on the source, it is generally accepted that these individuals have demonstrated remarkable resilience and adaptability in living with HIV over an extended period. Their experiences provide valuable insights into the long-term effects of HIV infection and treatment, as well as the importance of providing comprehensive care and support to those living with this chronic condition.

A condom is a thin sheath that covers the penis during sexual intercourse. It is made of materials such as latex, polyurethane, or lambskin and is used as a barrier method to prevent pregnancy and sexually transmitted infections (STIs). Condoms work by collecting semen when the man ejaculates, preventing it from entering the woman's body. They come in various sizes, shapes, textures, and flavors to suit individual preferences. It is important to use condoms correctly and consistently to maximize their effectiveness.

'Unsafe sex' is not a term that would be found in a formal medical dictionary or textbook, but it is commonly used to refer to sexual activities that carry a significant risk of transmission of sexually transmitted infections (STIs) and/or unwanted pregnancy. These risks can be reduced through the use of various protective measures.

The World Health Organization (WHO) defines 'unprotected sex' as sexual contact without the use of appropriate precautions, such as condoms, to prevent transmission of STIs. However, it is important to note that even the use of protection may not eliminate all risks associated with sexual activity. For example, some infections, like herpes or genital warts, can be transmitted through skin-to-skin contact, and condoms do not provide complete protection against these viruses.

In summary, 'unsafe sex' generally refers to sexual activities that carry a high risk of STIs and/or unwanted pregnancy due to the lack of appropriate protective measures.

AIDS-related opportunistic infections (AROIs) are infections that occur more frequently or are more severe in people with weakened immune systems, such as those with advanced HIV infection or AIDS. These infections take advantage of a weakened immune system and can affect various organs and systems in the body.

Common examples of AROIs include:

1. Pneumocystis pneumonia (PCP), caused by the fungus Pneumocystis jirovecii
2. Mycobacterium avium complex (MAC) infection, caused by a type of bacteria called mycobacteria
3. Candidiasis, a fungal infection that can affect various parts of the body, including the mouth, esophagus, and genitals
4. Toxoplasmosis, caused by the parasite Toxoplasma gondii
5. Cryptococcosis, a fungal infection that affects the lungs and central nervous system
6. Cytomegalovirus (CMV) infection, caused by a type of herpes virus
7. Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis
8. Cryptosporidiosis, a parasitic infection that affects the intestines
9. Progressive multifocal leukoencephalopathy (PML), a viral infection that affects the brain

Preventing and treating AROIs is an important part of managing HIV/AIDS, as they can cause significant illness and even death in people with weakened immune systems. Antiretroviral therapy (ART) is used to treat HIV infection and prevent the progression of HIV to AIDS, which can help reduce the risk of opportunistic infections. In addition, medications to prevent specific opportunistic infections may be prescribed for people with advanced HIV or AIDS.

I'm sorry for any confusion, but "Uganda" is not a medical term or concept. It is the name of a country located in East Africa, known officially as the Republic of Uganda. If you have any questions about medical terms or concepts, I would be happy to help with those!

I'm sorry for any confusion, but "Zimbabwe" is not a medical term. It's a country located in the southern part of Africa. If you have any questions about medical terms or concepts, I'd be happy to help answer those for you!

"HIV Seronegativity" by people in this website by year, and whether "HIV Seronegativity" was a major or minor topic of these ... "HIV Seronegativity" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "HIV Seronegativity" by people in Profiles. ... Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. Neurology. 2013 Dec 10 ...
HIV simple/rapid assays : operational characteristics (Phase I). Report 12: Simple rapid tests, whole blood specimens. by World ... Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant ...
HIV Infections / epidemiology * HIV Infections / prevention & control* * HIV Seronegativity* * HIV Seropositivity* * Humans ... safer conception strategies have been developed to help HIV-serodiscordant couples conceive a child without transmitting HIV to ... Estimated costs for the delivery of safer conception strategies for HIV-discordant couples in Zimbabwe: a cost analysis BMC ... 360 per couple over and above the cost of current HIV clinical practices. The cost of delivering the most commonly selected ...
HIV Seronegativity * Herpesvirus 4, Human / isolation & purification * Humans * Leukoplakia, Hairy / chemically induced* ... Patients and methods: An 81-year-old HIV-negative woman, treated for 3 months with topical steroids for oral lichen planus, ... It is found predominantly in HIV-positive patients and is considered a clinical indicator of immunosuppression. OHL has rarely ... been described in HIV-negative patients, being found most often in association with iatrogenic immunosuppression. OHL induced ...
In the absence of treatment, the risk of vertical transmission of HIV is as high as 25-30%. ... HIV) is regarded as one of the most effective public health initiatives in the United States. ... Repeat testing several months later usually confirms seronegativity in such cases. A positive test is sent for Western blot. ... All HIV-infected women with HIV RNA ,1,000 copies/mL (or unknown HIV RNA) near delivery should be administered intravenous (IV ...
In the absence of treatment, the risk of vertical transmission of HIV is as high as 25-30%. ... HIV) is regarded as one of the most effective public health initiatives in the United States. ... Repeat testing several months later usually confirms seronegativity in such cases. A positive test is sent for Western blot. ... All HIV-infected women with HIV RNA ,1,000 copies/mL (or unknown HIV RNA) near delivery should be administered intravenous (IV ...
Categories: HIV Seronegativity Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted ...
... and how to take care of yourself when you have HIV. ... Modes of HIV transmission and prevention Learn about HIV, its ... Verbal claims of seronegativity should be viewed with skepticism. When a couple, heterosexual or homosexual, is establishing a ... Latest HIV / AIDS Headlines. *HIV testing during early infection may reduce… *Antibody therapy opens door to potential new ... HIV infection is a sexually transmitted disease (STD). Like other STDs, HIV spreads bidirectionally and appears to be ...
... while the absence of such levels is considered seronegativity. The term serostatus is commonly used in HIV/AIDS prevention ... In the late 20th and early 21st centuries, social advocacy has emphasized the importance of learning ones HIV/AIDS serostatus ... July 2001). "The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals". American ... Articles with short description, Short description is different from Wikidata, Serology, HIV/AIDS). ...
HIV Seronegativity. , Humans. , Incidence. , Male. , Microbial Sensitivity Tests. , Middle Aged. , Mycobacterium tuberculosis. ...
... provides a recommended immunization schedule by medical condition and other indications for adults and adolescents with HIV ... Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity. AIDS. 1992;6(11 ... People with HIV should receive a complete COVID-‍19 vaccine series regardless of their CD4 count or HIV viral load (AIII). ... People with HIV should receive a complete COVID-‍19 vaccine series regardless of their CD4 count or HIV viral load (AIII). ...
HIV has been referred to by the acronym GRID (Gay-related immune deficiency), or even as the "gay cancer". HIVs public ... sexually protected relationship or a proof of seronegativity are in a similar situation to other candidates and yet the ... despite higher HIV incidence and prevalence rates among the MSM population, it can be said that MSM candidates with a ... his HIV status, the Court recognises that where a "restriction on fundamental rights applies to a particularly vulnerable group ...
In the absence of treatment, the risk of vertical transmission of HIV is as high as 25-30%. ... HIV) is regarded as one of the most effective public health initiatives in the United States. ... Repeat testing several months later usually confirms seronegativity in such cases. A positive test is sent for Western blot. ... All HIV-infected women with HIV RNA ≥400 copies/mL (or unknown HIV RNA) near delivery should be administered IV zidovudine (ZDV ...
Adult, Anti-HIV Agents, Drug Therapy, Combination, HIV Antibodies, HIV Infections, HIV Seronegativity, Humans, Male ... Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy. ... Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy. ...
The proportion of blood donors having at least one viral-TTI was 12.6% while the magnitudes of HIV, HBV, and HCV were 2.6, 5.8 ... Blood samples from volunteer donors collected; serum separated and screened with ELISA tests for detection of anti-HIV, ... Also encouragement of blood donation from voluntary donors and creating awareness on the general public regarding HIV, HBsAg ... Educational status and multiple sexual behaviors are significantly associated with HIV acquisition whilst marital status was ...
We investigated the prevalence and risk factors of TT seronegativity in a cohort of people living with HIV (PWH) in Belgium ... Tetanus seroprotection in people living with HIV: Risk factors for seronegativity, evaluation of medical history and a rapid ... Infecções por HIV , Tétano , Anticorpos Antibacterianos , Contagem de Linfócito CD4 , Estudos Transversais , Infecções por HIV/ ... socio-demographic and educational factors were associated with TT seronegativity while HIV-related factors were not, indicating ...
Torre P, Hoffman HJ, Springer G, Cox C, Young MA, Margolick JB, Plankey M. Hearing loss among HIV-seropositive and HIV- ...
We used β-distributed multivariable models to analyse differences in HRQoL scores between HIV-negative and HIV-positive ... INTERPRETATION: ART is successful in helping to reduce inequalities in HRQoL between HIV-positive and HIV-negative individuals ... and those in HIV care but not on ART (-0·008, -0·01 to -0·004; p=0·001) than in HIV-negative people, but the magnitudes of ... We aimed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South Africa. METHODS: As part of the HPTN ...
1. Subjects with HIV and an undetectable viral load and CD4 + T-cell (CD4+) counts ≥ 350 cells/mL may be enrolled, but must be ... Serology testing is not required if seronegativity is documented in the medical history, and if there are no clinical signs ... Current evidence of uncontrolled human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at ... suggestive of HIV or hepatitis infections, or suspected exposure. The following exceptions apply for subjects with positive ...
Adult, DNA Virus Infections, DNA Viruses, Female, HIV Seronegativity, HIV Seropositivity, Homosexuality, Male, Humans, Male, ...
They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the ... They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the ... HIV Serodiagnoses HIV Serodiagnosis HTLV III Serodiagnosis HTLV III Serology HTLV-III Serodiagnoses HTLV-III Serodiagnosis HTLV ... Serodiagnoses, HIV Serodiagnoses, HTLV-III Serodiagnosis, AIDS Serodiagnosis, HIV Serodiagnosis, HTLV III Serodiagnosis, HTLV- ...
... to understand the host responses that underlie the persistent seronegativity of certain individuals despite high levels of HIV ... the objective of which is to gain a better understanding of HIV-positive slow progressors by examining their virus type, ... factors determining their rate of HIV progression, and how their immune systems function. She has contributed to more than a ... exposure and the slow disease progression observed in certain population of people living with HIV. ...
In contrast, CD68-positive microglia were enhanced in both HIV- positive and HIV-negative drug users, considerably above the ... In this study, samples of frontal and temporal lobes, and basal ganglia, were selected from 12 HIV-positive drug users who had ... Drug use alone is associated with significant upregulation of microglia and this may predispose to HIV infection of the nervous ... by HIV-1 can occur early, even around the time of seroconversion, and evidence from animal studies supports this. However, the ...
In contrast, CD68-positive microglia were enhanced in both HIV- positive and HIV-negative drug users, considerably above the ... In this study, samples of frontal and temporal lobes, and basal ganglia, were selected from 12 HIV-positive drug users who had ... Drug use alone is associated with significant upregulation of microglia and this may predispose to HIV infection of the nervous ... by HIV-1 can occur early, even around the time of seroconversion, and evidence from animal studies supports this. However, the ...
... mixed cellularity with HIV seropositivity and nodular sclerosis with HIV seronegativity), TB association (higher with HIV ... The relative risk is 10-20 fold higher with HIV seropositivity, compared to the general population. HIV associated Hodgkin ... A comparison of the HIV seropositive and HIV seronegative patients shows that there is a statistically significant difference ... However, the median survival was shorter in HIV seropositive compared to HIV seronegative individuals. Conclusion As compared ...
HIV Seronegativity [G12.400] * Immune Evasion [G12.413] * Immune Reconstitution [G12.432] * Immunity [G12.450] * ... This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS. ... This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS. ...
HIV Seronegativity [G12.400] * Immune Evasion [G12.413] * Immune Reconstitution [G12.432] * Immunity [G12.450] * ...

No FAQ available that match "hiv seronegativity"

No images available that match "hiv seronegativity"